

# Global Muscarinic Acetylcholine Receptor M2 Trends, Regulations and Competitive Landscape Outlook To 2021

PUNE, MAHARASHTRA, INDIA, April 12, 2018 /EINPresswire.com/ --Muscarinic Acetylcholine Receptor M2

## Summary

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Muscarinic cholinergic receptor 2 is an acetylcholine receptor. It is expressed in various regions of the brain including the cerebellum, cerebral cortex, hippocampus, medulla, striatum, and thalamus, and in lung and prostate.



It mediates smooth muscle contractility. Increase in M2 receptor has been associated with depression.

The report 'Muscarinic Acetylcholine Receptor M2 (CHRM2) - Pipeline Review, H1 2017' outlays comprehensive information on the Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

Click here for sample report @ <a href="http://www.wiseguyreports.com/sample-request/1510548-muscarinic-acetylcholine-receptor-m2-chrm2-pipeline-review-h1-2017">http://www.wiseguyreports.com/sample-request/1510548-muscarinic-acetylcholine-receptor-m2-chrm2-pipeline-review-h1-2017</a>

## Scope of The Report

- The report provides a snapshot of the global therapeutic landscape for Muscarinic Acetylcholine Receptor M2 (CHRM2)
- The report reviews Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics and enlists all their major and minor projects

#### **Table of Contents**

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Overview

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Companies Involved in Therapeutics Development

Allergan Plc

Anavex Life Sciences Corp

FemmePharma Global Healthcare Inc

Juniper Pharmaceuticals Inc

#### .Continued

For Detailed Reading Please visit @ <a href="https://www.wiseguyreports.com/reports/1510548-muscarinic-acetylcholine-receptor-m2-chrm2-pipeline-review-h1-2017">https://www.wiseguyreports.com/reports/1510548-muscarinic-acetylcholine-receptor-m2-chrm2-pipeline-review-h1-2017</a>

## About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Norah Trent WiseGuy Research Consultants Pvt. Ltd. +1 646 845 9349 / +44 208 133 9349 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.